Clinical Trial Search

Primary: Mean Change in Visual Acuity From Baseline — 2.8; 0.2 letters

Primary: Effect of Olaparib on Exposure to Tamoxifen - Cmax ss — 130.3; 154.2; 162.9; 149.1 mcg/mL

Primary: Changes in Diversity of Gut Microbiota 16S rRNA Gene Sequences With Regard to Time. — 316.383; 302.400; 283.058 Avg. Operational Taxonomic Units

Primary: Number of Participants With Adverse Events — 10; 9; 0; 10 participants

Primary: Overall Closure Time — 78; 216 seconds — p=<0.001

Primary: Number of Subjects With Adverse Events as a Measure of Safety and Tolerability — 24; 83; 33; 18 participants

Primary: The Primary End Point Was the Percentage of Patients With a Negative Mycological Culture. — 12; 10 percentage of participants — p=<0.05

Primary: Percentage of Participants With Adverse Events (AEs)/Adverse Drug Reactions (ADRs), Serious AEs (SAEs)/Serious ADRs (SADRs), and Unexpected AEs/ADRs — 32.98; 9.85…

Primary: Point Prevalence Abstinence — 15; 5 participants

Primary: The Proportion of Subjects With >50% Thrombolysis — 43.8; 47.4; 81.0; 47.4 percentage of participants

Primary: Plasma Phylloquinone — 0.3; 2.3 nmol/L

Primary: Grading Scale for Visual Evaluation of Skin Condition — 0; 0; 0; 0 Scores Ranging (0-7)

Primary: To Evaluate User Satisfaction With and Perceived Utility of the "Caring for You, Caring for Me" Caregiver Educational Program Among Formal (VHA Staff) and Informal…

Primary: Percentage of Participants Achieving Sustained Virologic Response 12 Weeks After the End of All Study Therapy (SVR12) — 100.0; 95.8; 100.0; 82.8 percentage of participants

Primary: Change in Intraocular Pressure From Baseline to Week 12 — 6.12; 6.91 mm Hg — p=<0.01